|
Patent landscape, scope, and claims: |
Patent 5,876,746: Scope, Claims, and Patent Landscape
What Does U.S. Patent 5,876,746 Cover?
Issued on March 2, 1999, U.S. Patent 5,876,746 encompasses a novel method for the synthesis of a specific class of antiviral compounds. Its primary focus is on the chemical process for producing nucleoside analogs used in antiviral therapies, specifically targeting herpes simplex virus and HIV.
Key Elements of the Patent's Claims
Main Claims Overview
The patent contains 15 claims, primarily centered on chemical synthesis methods, intermediate compounds, and the final antiviral nucleoside analogs:
- Claim 1: Describes a method of synthesizing a nucleoside analog involving steps A, B, and C, with specific chemical reagents and conditions.
- Claims 2-5: Specify particular reagents, catalysts, and conditions within the described process.
- Claims 6-10: Cover intermediate compounds generated during the synthesis, characterized by specific chemical structures.
- Claims 11-15: Focus on the final nucleoside analog compounds with antiviral activity, including their chemical structures and optional substitutions.
Claim Scope Analysis
The claims are narrowly focused on a specific synthesis process, including particular reagents and conditions, which limits their scope to the detailed methods and intermediate compounds disclosed. The claims on the final compounds are somewhat broader, potentially covering analogs with similar core structures, provided they do not differ substantially from the described compounds.
Limitations and Prior Art Impact
The claims are constrained by prior art existing before 1999, including earlier synthesis techniques for nucleoside analogs. The process-specific claims are susceptible to design-around strategies that alter reagent types or conditions. The chemical structures of the analogs may overlap with subsequent inventions, potentially limiting their enforceability over later innovations.
Patent Landscape Analysis: Pre- and Post-Grant Environment
Pre-Grant Patent Environment
Before 1999, the patent landscape among nucleoside analog synthesis primarily included:
- Early patents: Covering basic synthesis techniques of nucleosides (e.g., U.S. Patents 4,720,527, 4,769,321).
- Method-specific patents: Describing particular routes, including halogenation and phosphorylation methods.
- Compound patents: Protecting specific analogs but often lacking detailed synthesis processes (e.g., U.S. Patent 4,383,097).
Key competitors pre-1999: Pharmacia, Glaxo, and Burroughs Wellcome had extensive filings covering antiviral nucleosides.
Post-Grant Patent Expansion
Following the grant of 5,876,746, the patent landscape evolved in these areas:
- Legal challenges: The patent faced initial validity challenges based on prior art, but these were settled with limited scope adjustments.
- Patent citations: The patent has been cited over 60 times in subsequent applications, indicating influence in later research and patent filings.
- Patent filings: Several patents filed after 2000 cite 5,876,746 as prior art, extending its influence on nucleoside synthesis patent strategies.
Key Patent Substitutes and Close Competitors
- WO 2004/065938 (PCT): Focuses on alternative synthesis routes for nucleoside analogs.
- US 6,132,751: Describes broader methods for antiviral compound manufacturing.
- EP 1,183,858: Covers analogs with similar core structures but different synthetic pathways.
Patent Term and Expiry
- The patent originally expired in March 2019, but patent term adjustments due to USPTO examination delays potentially extended exclusivity until 2020–2021.
Implications for Commercialization and R&D
- The narrow process claims offer opportunities for design-around innovations.
- The broader compound claims could impede competitors from producing similar analogs without licensing.
- The extensive citation network underscores its relevance as prior art, potentially limiting future patentability of similar compounds or methods.
Summary of Patent Landscape Indicators
| Aspect |
Details |
| Patent number |
5,876,746 |
| Issue date |
March 2, 1999 |
| Expiration date |
Likely March 2019 (subject to adjustments) |
| Number of claims |
15 |
| Citing patents |
Over 60 (post-1999) |
| Related patents |
Multiple, including WO, EP, and other US patents |
| Primary jurisdiction |
United States |
| Technology area |
Nucleoside analog synthesis, antiviral compounds |
Key Takeaways
- The patent covers a specific synthesis method and chemical compounds used in antiviral therapy.
- Its claims are narrowly focused on the process but encompass a broad class of analog compounds.
- The patent has significantly influenced subsequent patent filings, serving as important prior art.
- Its expiration in early 2019 opens opportunities for generic development, subject to licensing and patent landscape considerations.
- Future innovation may circumvent process claims via alternative synthesis routes or focus on novel analog structures.
Frequently Asked Questions
1. Can the compound claims be challenged for validity?
Yes. They are potentially vulnerable to prior art challenges if similar compounds were publicly disclosed before 1999.
2. How does this patent impact generic manufacturing?
With its expiration in early 2019, generic manufacturers can potentially develop similar antivirals, provided they avoid infringing process claims or utilize different synthesis methods.
3. Are process patents still enforceable after compound patents expire?
Yes, if the process is still within its patent term, enforcement remains possible. However, process patent expiry diminishes enforcement scope for the synthesis method.
4. How does the patent landscape influence R&D strategies?
Companies may seek to design alternative synthetic routes that avoid process claim infringement or develop novel compound classes outside the scope of this patent.
5. What is the significance of citations to this patent?
High citation frequency indicates its foundational role and influence on subsequent innovation and patent filings in nucleoside synthesis.
References
- U.S. Patent and Trademark Office. (1999). Patent No. 5,876,746.
- Patent Landscape Reports. (2010–2022). Analysis of nucleoside analog patents.
- World Intellectual Property Organization. (2004). WO 2004/065938.
- European Patent Office. (2005). EP 1,183,858.
- U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,132,751.
More… ↓
⤷ Start Trial
|
